taskset -c 0-7 python pipeline.py
2026-03-26 15:49:33.624759902 [W:onnxruntime:Default, device_discovery.cc:132 GetPciBusId] Skipping pci_bus_id for PCI path at "/sys/devices/LNXSYSTM:00/LNXSYBUS:00/ACPI0004:00/VMBUS:00/5620e0c7-8062-4dce-aeb7-520c7ef76171" because filename ""5620e0c7-8062-4dce-aeb7-520c7ef76171"" dit not match expected pattern of [0-9a-f]+:[0-9a-f]+:[0-9a-f]+[.][0-9a-f]+
INFO:nv_ingest_api.util.system.hardware_info:Detected 32 logical cores via psutil.
INFO:nv_ingest_api.util.system.hardware_info:Detected 16 physical cores via psutil.
INFO:nv_ingest_api.util.system.hardware_info:Detected 8 cores via os.sched_getaffinity.
INFO:nv_ingest_api.util.system.hardware_info:Raw CPU limit determined: 8.00 (Method: sched_affinity)
INFO:nv_ingest_api.util.system.hardware_info:Effective CPU core limit determined: 8.00 (Method: sched_affinity)
INFO:nv_ingest.framework.orchestration.ray.util.pipeline.pipeline_runners:Launching pipeline in Python subprocess using multiprocessing.
INFO:nv_ingest.framework.orchestration.ray.util.pipeline.pipeline_runners:Pipeline subprocess started (PID=2238869)
Waiting for pipeline to initialize...
Pipeline ready. Connecting client...

=== STEP 1: Testing basic text extraction ===
Starting ingestion...
Processing:   0%|                                                                            | 0/1 [00:00<?, ?doc/s]INFO:nv_ingest_client.client.client:Starting batch processing for 1 jobs with batch size 32.
Processing: 100%|████████████████████████████████████████████████████████████████████| 1/1 [00:31<00:00, 31.13s/doc]INFO:nv_ingest_client.client.client:Batch processing finished. Success: 1, Failures: 0. Total accounted for: 1/1
Processing: 100%|████████████████████████████████████████████████████████████████████| 1/1 [00:31<00:00, 31.13s/doc]
Total time: 31.13 seconds

Results:  1
Failures: 0

=== STEP 1 SUCCEEDED ===
Urine R/M Urine Sample
Accession No: DEMO_BARCODE Collected On: 21-Jan-25 13:40 Received On: 21-Jan-25 14:31 Approved On: 21-Jan-25 17:23
Observation Result Unit Biological Ref. Interval Method
Physical Examination
Urine Quantity 7.5 mL 7 - 8 Physical Examination
Urine Colour Pale Yellow Pale Yellow Physical Examination
Urinary Transparency Clear Clear Physical Examination
Biochemical Examination
Urinary pH 5.5 pH 6 .0 - 8.0 pH bromothymol blue
Urinary Specific Gravity 1.025 1.005 - 1.030 Ethyleneglycol-bis t.a.a.
Urinary Protein Negative Negative Tetrachlorophenol
Urinary Glucose 1+ Negative glucose-oxidase-peroxidase
Urinary Ketones Negative Negative Sodium Nitroprusside
Urobilinogen Negative Negative Methoxybenzene Diazonium
Urine Bilirubin Negative Negative Dichlorobenzene-diazonium
Urinary Nitrites Negative Negative hydroxy
Blood [In Urine] Negative Negative Tetramethylbenzidine
Leukocyte esterase Negative Negative indoxyl-ester-diazonium
Microscopic Examination
Pus Cells [In Urine] 1-2 /HPF 1 - 2 /HPF Flow Micro Imaging
Epithelial Cells (Squamous) 1-2 /HPF 0-2/HPF Flow Micro Imaging
Epithelial Cells (Non-Squamous) NIL /HPF 0-2/HPF Flow Micro Imaging
Urinary RBC NIL /HPF NIL /HPF Flow Micro Imaging
Hyaline Casts NIL /LPF 0-2/LPF Flow Micro Imaging
Pathological Casts NIL /LPF 0-1/LPF Flow Micro Imaging
Yeast Cells NIL /HPF 0-1/HPF Flow Micro Imaging
Crystals NIL /HPF NIL/HPF Flow Micro Imaging
Other Morphology NIL NIL Microscopy
-----------------------------------------------------------------------
Remarks:
Sample Quantity is observed after transfer to a Urinalysis Vacutainer Tube for preservation of sample.
Note for Female Patients: If the urine is collected during menstruation, red cells may be present in the urine.
Microscopy: Microscopy may have supplemented automated measurements, wherever necessary.
-----------------------------------------------------------------------
Advise: Please correlate results clinically.
-----------------------------------------------------------------------
In case of any unexpected or alarming results, please contact us immediately for re-confirmation, clarifications, and rectifications, if needed.
Patient Name : Demo Patient Name Lab No : Demo Visit No
Age / Sex : 60 Y / M Registration On : 21-Jan-25 13:40
Referred By : DEMO HOSPITAL Patient ID : UHID.DEMO.001
Centre : HOD Head Office
This is a Sample Report - Actual report will vary in values, format, ranges etc
Scan to Validate
Page 1 of 13
Sample Report
Digital X-Ray Chest PA Approved On: 21-Jan-25 19:58
FRONTAL RADIOGRAPH CHEST (PA VIEW)
Bilateral lung fields show no obvious parenchymal lesion.
Cardiac size is normal.
Hila are unremarkable.
Both domes of diaphragm are normal.
Both cardiophrenic and costophrenic angles are normal.
Bony thoracic cage appears normal.
ADVISED: CLINICAL CORRELATION.
Patient Name : Demo Patient Name Lab No : Demo Visit No
Age / Sex : 60 Y / M Registration On : 21-Jan-25 13:40
Referred By : DEMO HOSPITAL Patient ID : UHID.DEMO.001
Centre : HOD Head Office
This is a Sample Report - Actual report will vary in values, format, ranges etc
Scan to Validate
Page 2 of 13
Sample Report
Patient Name : Demo Patient Name Lab No : Demo Visit No
Age / Sex : 60 Y / M Registration On : 21-Jan-25 13:40
Referred By : DEMO HOSPITAL Patient ID : UHID.DEMO.001
Centre : HOD Head Office
This is a Sample Report - Actual report will vary in values, format, ranges etc
Scan to Validate
Page 3 of 13
Sample Report
Ultrasound Whole Abdomen Approved On: 21-Jan-25 16:29
ULTRASOUND WHOLE ABDOMEN
FINDINGS:
Liver is enlarged in size (~ 164 mm) and shows increase in parenchymal echogenicity. Intrahepatic biliary
radicals are normal. Portal vein is normal in course and caliber.
Gall bladder is distended and shows an intraluminal echogenic focus (measuring ~ 3 mm) without
posterior shadowing in relation to the posterior wall - it may represent polyp / sludge. Wall thickness is
normal. Common bile duct is not dilated.
Pancreas is normal in size, outline and echotexture.
Spleen is normal in size and echotexture.
Right kidney is normal in size (~ 109 mm), shows lobulated outline and increase in cortical
echogenicity. Corticomedullary differentiation is maintained. No evidence of hydronephrotic changes seen.
Left kidney is normal in size (~ 110 mm), shows lobulated outline and increase in cortical
echogenicity. Corticomedullary differentiation is maintained. No evidence of hydronephrotic changes seen.
Few tiny intramedullary echogenic foci are seen in bilateral kidneys - likely renal sinus fat / concretions.
Urinary bladder is seen in distended state. Wall thickness is normal. No obvious calculus or mass lesion is seen.
Prevoid urine volume is ~ 247 cc.
Postvoid residual urine volume is Nil.
Prostate is normal in size, outline and echotexture.
No free fluid is seen.
A small midline defect of size ~ 14 mm is seen in the linea alba in umbilical region with herniation of
omental fat through it - umbilical hernia.
IMPRESSION:-
- Hepatomegaly with fatty changes (grade I - II)
- Gall bladder polyp / sludge
- ? Medical renal disease
- Umbilical hernia
Patient Name : Demo Patient Name Lab No : Demo Visit No
Age / Sex : 60 Y / M Registration On : 21-Jan-25 13:40
Referred By : DEMO HOSPITAL Patient ID : UHID.DEMO.001
Centre : HOD Head Office
This is a Sample Report - Actual report will vary in values, format, ranges etc
Scan to Validate
Page 4 of 13
Sample Report
ADVICE: CLINICAL, KFT, LFT AND ELASTOGRAPHY CORRELATION
In case of any discrepancy due to typing error, kindly get it rectified immediately. This is professional opinion, not a diagnosis.
ECG Approved On: 21-Jan-25 14:10
In case of any discrepancy due to typing error, kindly get it rectified immediately. This is professional opinion, not a diagnosis.
Patient Name : Demo Patient Name Lab No : Demo Visit No
Age / Sex : 60 Y / M Registration On : 21-Jan-25 13:40
Referred By : DEMO HOSPITAL Patient ID : UHID.DEMO.001
Centre : HOD Head Office
This is a Sample Report - Actual report will vary in values, format, ranges etc
Scan to Validate
Page 5 of 13
Sample Report
CBC EDTA Whole Blood Sample
Accession No: DEMO_BARCODE Collected On: 21-Jan-25 13:40 Received On: 21-Jan-25 14:31 Approved On: 21-Jan-25 17:23
Observation Result Unit Biological Ref. Interval Method
Hemoglobin 13.6 gm/dL 13.0 - 17.0 Photometric Measurement
Total RBC 4.69 million/µL 4.5 - 5.5 Coulter Principle
Platelet Count 318 X 10³ / µL 150 - 410 x 10³/µL Impedance
Total Leucocyte Count (WBC) 7.09 X 10³ / µL 4.0 - 10.0 Flow Cytometry
Differential Leucocyte Count (DLC)
Neutrophils 50.2 % 40 - 80 Flow Cytometry
Lymphocytes 40.0 % 20 - 40 Flow Cytometry
Monocytes 5.7 % 2 - 10 Flow Cytometry
Eosinophils 3.3 % 1 - 6 Flow Cytometry
Basophils 0.8 % 0 - 1 Flow Cytometry
Absolute Neutrophil Count 3.56 X 10³ / µL 2.0 - 7.5 Flow Cytometry
Absolute Lymphocyte Count 2.84 X10³ / µL 1.0 - 4.0 Flow Cytometry
Absolute Monocyte Count 0.4 X 10³ / µL 0.2 - 1.0 Flow Cytometry
Absolute Eosinophil Count 0.23 X 10³ / µL 0.02 - 0.5 Flow Cytometry
Absolute Basophil Count 0.07 X10³ / µL 0.00 - 0.30 Flow Cytometry
Indices
Hematocrit (PCV) 43.8 % 40 - 50 Calculated
Mean Corpuscular Volume (MCV) 93.3 fL 83 - 101 Calculated
Mean Corp. Hemoglobin (MCH) 28.9 pg 27 - 32 Calculated
MCH Concentration (MCHC) 30.9 g/dl 31.5 - 34.5 Calculated
Red Cell Dist. Width (RDW-CV) 16.2 % 11.5 - 14.5 Calculated
Red Cell Dist. Width (RDW-SD) 55.5 fL 39 - 46 Calculated
Mean Platelet Volume (MPV) 10.7 fL 7-5 - 12.0 Calculated
P-LCC 95 10^9/L 30-90 SF Cube
P-LCR 29.87 % 11-45 Calculated
Neutrophil-Lymphocyte Ratio (NLR) 1.26 Ratio Calculated
Mentzer Index 19.89 Index Calculated
-----------------------------------------------------------------------------------------------------------------
Remarks: Please correlate with clinical conditions
-----------------------------------------------------------------------------------------------------------------
In case of any unexpected or alarming results, please contact us immediately for re-confirmation, clarifications, and rectifications, if needed.
Glucose Fasting Sodium Fluoride Sample
Accession No: DEMO_BARCODE Collected On: 21-Jan-25 13:40 Received On: 21-Jan-25 14:39 Approved On: 21-Jan-25 15:07
Observation Result Unit Biological Ref. Interval Method
Blood Sugar Fasting 88 mg/dL 70 - 100 GOD/POD, colorimetric
Patient Name : Demo Patient Name Lab No : Demo Visit No
Age / Sex : 60 Y / M Registration On : 21-Jan-25 13:40
Referred By : DEMO HOSPITAL Patient ID : UHID.DEMO.001
Centre : HOD Head Office
This is a Sample Report - Actual report will vary in values, format, ranges etc
Scan to Validate
Page 6 of 13
Sample Report
---------------------------------------------------------------------------------
Sample Type: Sodium Fluoride; A blood sample will be taken after 8 - 12 hours of fasting.
Method: Glucose oxidase hydrogen peroxidase
Technology: Dry Chemistry (VITROS MicroSlide, MicroSensor & Intellicheck Technology)
Analyzer: Fully Automated Integrated Biochemistry & ImmunoAssay Analyzer: VITROS 5600
---------------------------------------------------------------------------------
Remarks: Please correlate clinically
Note: Blood glucose level is maintained by a very complex integrated mechanism involving a critical interplay of the release of hormones and action of enzymes on key
metabolic pathways. If postprandial glucose is lower than fasting glucose, it is termed as postprandial reactive hypoglycemia (PRH). The possible cause of PRH are high insulin
sensitivity, exaggerated response of insulin and glucagon-like peptide 1, defects in counter-regulation, very lean individuals, anxious individuals, after massive weight
reduction, women with lower body overweight physical activity prior test, hypoglycemic medication, deliberately eating less or eat a non-carbohydrate meal before testing.
---------------------------------------------------------------------------------
Patient Name : Demo Patient Name Lab No : Demo Visit No
Age / Sex : 60 Y / M Registration On : 21-Jan-25 13:40
Referred By : DEMO HOSPITAL Patient ID : UHID.DEMO.001
Centre : HOD Head Office
This is a Sample Report - Actual report will vary in values, format, ranges etc
Scan to Validate
Page 7 of 13
Sample Report
Lipid Profile Serum Sample
Accession No: DEMO_BARCODE Collected On: 21-Jan-25 13:40 Received On: 21-Jan-25 14:39 Approved On: 21-Jan-25 15:07
Observation Result Unit Biological Ref. Interval Method
Total Cholesterol 192 mg/dL <200 Enzymatic (CHE/CHO/POD)
Triglyceride 200 mg/dL <150 Enzymatic, Endpoint
HDL Cholesterol 50 mg/dL >45 Direct Measure, PTA / MgCl2
VLDL Cholesterol 40 mg/dL 5-40 Calculated
LDL Cholesterol 102 mg/dL <100 Friedewald Formula (Calculated)
Non-HDL Cholesterol 142 mg/dL <130 Calculated
LDL / HDL Ratio 2.04 Ratio 1.5-3.5 Calculated
TC / HDL Ratio 3.84 Ratio 3-5 Calculated
-----------------------------------------------------------------------------------------------------
Clinical Decision Limits* Optimal Above Optimal Borderline High High Very High
Triglycerides <150 - 150-199 200-499 >=500
Total Cholesterol <200 200-239 - >=239 -
LDL Cholesterol <100 100-129 130-159 160-189 >=189
HDL Cholestrol >45 - 40-45 <40 -
Non HDL Cholesterol** <130 130 - 159 160 - 189 190 - 219 >=220
* Clinical Decision Limits are suggested from Tietz Fundamentals Of Clinical Chemistry And Molecular Diagnostics 8th Edition
** Suggested from National Lipid Association Recommendations for Patient Centered Management of Dyslipidemia: Part 1—Full Report (Volume 9, Issue 2, P129-169, March
01,2015, Terry A. Jacobson, MD et al.
-----------------------------------------------------------------------------------------------------
Analyzer: Fully Automated Integrated Biochemistry and ImmunoAssay Analyzer: VITROS 5600
Technology: Dry Chemistry (VITROS MicroSlide, MicroSensor & Intellicheck Technology)
-----------------------------------------------------------------------------------------------------
Reports of Lipid Profile are best obtained with 10 hours fasting.
-----------------------------------------------------------------------------------------------------
Clinical Significance:
- Triglyceride: Very high levels of Triglyceride can be indicative of a significantly higher risk of coronary vascular disease. Elevation of triglyceride can be seen with fasting less
than 12 hours, obesity medication, alcohol intake, diabetes mellitus or pancreatitis.
- Total Cholestrol: its fractions and triglycerides are the important plasma lipids identifying cardiovascular risk factor and in the management of cardiovascular disease. Values
above 220 mg/dl are associated with increased risk of CHD regardless of HDL & LDL value.
- HDL - Cholestrol: Low levels of HDL are associated with an increased risk of coronary vascular disease even in the face of desirable levels of Cholesterol and LDL-Cholestrol
- LDL - Cholestrol: levels can be strikingly altered by thyroid, renal and liver disease as well as hereditary factors.In case Triglyceride levels are more than 400 mg/dl, the
patient is advised for a direct-LDL Cholesterol test.
-----------------------------------------------------------------------------------------------------
Remarks: Please correlate results clinically.
-----------------------------------------------------------------------------------------------------
Patient Name : Demo Patient Name Lab No : Demo Visit No
Age / Sex : 60 Y / M Registration On : 21-Jan-25 13:40
Referred By : DEMO HOSPITAL Patient ID : UHID.DEMO.001
Centre : HOD Head Office
This is a Sample Report - Actual report will vary in values, format, ranges etc
Scan to Validate
Page 8 of 13
Sample Report
Liver Function Test Serum Sample
Accession No: DEMO_BARCODE Collected On: 21-Jan-25 13:40 Received On: 21-Jan-25 14:39 Approved On: 21-Jan-25 15:07
Observation Result Unit Biological Ref. Interval Method
Total Protein 8.2 g/dL 6.5-7.8 Biuret, No Serum Blank
Albumin 4.8 g/dL 4.2 - 5.0 Bromocresol Green
Globulin 3.4 gm/dL 2.0-3.5 Calculated
A/G Ratio 1.41 Ratio 1.5-2.5 Calculated
Total Bilirubin 0.65 mg/dL 0.2-1.3 Azobilirubin/dyphylline
Conjugated Bilirubin 0.4 mg/dL <0.3 Calculated
Unconjugated Bilirubin 0.25 mg/dL <1.1 Spectrophotometry
SGOT (AST) 21 U/L 18-39 Enzymatic Colorimetric
SGPT (ALT) 20 U/L 4-50 UV with P5P
SGOT/SGPT Ratio 1.05 Ratio Calculated
Alkaline Phosphatase 57 U/L 50 - 116 PNPP, AMP buffer
Gamma Glutamyl Transferase 32 U/L 13 - 109 G-glutamyl-p-nitroanilide
-----------------------------------------------------------------------------------------------------------------
Clinical Significance of LFT:e clinical suspicion of liver disease usually leads to the measurement of the liver function tests (LFT) which include measurement of several
enzymes, serum bilirubin and albumin. These parameters may point to an underlying pathological process and direct further investigation. The aim of investigation in patients
with suspected liver disease are: ·To detect hepatic abnormality · Measurement of severity of liver damage · Identify the specific cause ·Investigate possible complications
---------------------------------------------------------------------------------
Technology: Dry Chemistry (VITROS MicroSlide, MicroSensor and Intellicheck Technology)
Analyzer:Fully Automated Biochemistry and ImmunoAssay Analyzer: VITROS 5600
---------------------------------------------------------------------------------
Advise:Please correlate results clinically.
---------------------------------------------------------------------------------
Kidney Function Test Serum Sample
Accession No: DEMO_BARCODE Collected On: 21-Jan-25 13:40 Received On: 21-Jan-25 14:39 Approved On: 21-Jan-25 15:07
Observation Result Unit Biological Ref. Interval Method
Blood Urea 53 mg/dL 19 - 43 Urease, Colorimetric
Blood Urea Nitrogen 24.77 mg/dL 9-20 Calculated
Creatinine 1.41 mg/dL 0.6-1.25 Enzymatic
Estimated GFR 57.10 mL/min/1.73m2 Calculated By CKD-EPI(2021)
Uric Acid 5.7 mg/dL 3.5 - 8.5 Uricase , Colorimetric
Calcium 9.5 mg/dL 8.4 - 10.2 Arsenazo III
Phosphorus 3.4 mg/dL 2.5 - 4.5 Phosphomolybdate reduction
BUN/Creatinine Ratio 17.57 Ratio Calculated
Urea/Creatinine Ratio 37.59 Ratio Calculated
Electrolytes
Sodium 139 mmol/L 137-145 ISE Direct
Potassium 5.2 mmol/L 3.5 - 5.1 ISE Direct
Chloride 104 mmol/L 98 - 107 ISE Direct
Patient Name : Demo Patient Name Lab No : Demo Visit No
Age / Sex : 60 Y / M Registration On : 21-Jan-25 13:40
Referred By : DEMO HOSPITAL Patient ID : UHID.DEMO.001
Centre : HOD Head Office
This is a Sample Report - Actual report will vary in values, format, ranges etc
Scan to Validate
Page 9 of 13
Sample Report
-----------------------------------------------------------------------------------------------------------------
Classification of eGFR by UK Kidney Association (2017):
eGFR (ml/min/1.73 m2) GFR Category Significance
>90 G1 Normal Renal Function
60-90 G2 Mild Impairment of Renal Function
45-59 G3a Impaired Kidney Function
30-44 G3b Impaired Kidney Function
15-29 G4 Significant Impairment of Renal Function
<15 G5 End-Stage Renal Failure (ESRF)
-----------------------------------------------------------------------------------------------------------------
Technology: Dry Chemistry (VITROS MicroSlide, MicroSensor and Intellicheck Technology)
Remarks: Please correlate results clinically.
-----------------------------------------------------------------------------------------------------------------
Patient Name : Demo Patient Name Lab No : Demo Visit No
Age / Sex : 60 Y / M Registration On : 21-Jan-25 13:40
Referred By : DEMO HOSPITAL Patient ID : UHID.DEMO.001
Centre : HOD Head Office
This is a Sample Report - Actual report will vary in values, format, ranges etc
Scan to Validate
Page 10 of 13
Sample Report
Vitamin B12 Serum Sample
Accession No: DEMO_BARCODE Collected On: 21-Jan-25 13:40 Received On: 21-Jan-25 14:39 Approved On: 21-Jan-25 16:10
Observation Result Unit Biological Ref. Interval Method
Vitamin B-12 971 pg/mL 239-931 CLIA
-----------------------------------------------------------------------------------------------------------------
Technology: VITROS Microwell, Microsensor and Intellicheck Technology
Analyzer: Fully Automated Integrated Biochemistry and ImmunoAssay Analyzer: VITROS 5600
-----------------------------------------------------------------------------------------------------------------
Remarks: Please correlate results clinically.
-----------------------------------------------------------------------------------------------------------------
Vitamin D, 25 - Hydroxy Serum Sample
Accession No: DEMO_BARCODE Collected On: 21-Jan-25 13:40 Received On: 21-Jan-25 14:39 Approved On: 21-Jan-25 15:41
Observation Result Unit Biological Ref. Interval Method
25-OH Vitamin D (Total) 32.2 ng/mL 20 - 100 CLIA
---------------------------------------------------------------------------------
Technology: VITROS Microwell, Microsensor, and Intellicheck Technology
Analyzer: Fully Automated Integrated Biochemistry and ImmunoAssay: VITROS 5600
--------------------------------------------------------------------------------
Clinical Significance: The major circulating form of vitamin D is 25-hydroxyvitamin D (25(OH)D); thus, the total serum 25(OH)D level is currently considered the best
indicator of vitamin D supply to the body from cutaneous synthesis and nutritional intake. The reference range of the total 25(OH)D level is 20-100 ng/mL.
There are two principal forms of vitamin D: D2 and D3. Many of the currently available assays measure and report on both vitamin D2 and D3 metabolites. This can be useful
in studies evaluating the contribution of vitamin D2 and D3 to overall vitamin D status. 25-hydroxyvitamin D (25(OH)D) is the major circulating form of vitamin D; thus, the
total serum 25(OH)D level is currently considered the best indicator of vitamin D supply to the body from cutaneous synthesis and nutritional intake.
One exception is that 25(OH)D levels do not indicate clinical vitamin D status in patients with chronic renal failure or type 1 vitamin D-dependent rickets or when calcitriol (1,25-
dihydroxy vitamin D) is used as a supplement. Interpretation of 25(OH)D can be challenging owing to wide variability in patient's weight, ethnicity, assays, laboratory
procedures and validation of reference ranges.
Vitamin D deficiency is defined by most experts as a serum 25(OH)D level of less than 20 ng/mL.
Vitamin D insufficiency has been defined as a serum 25(OH)D level of 20-29 ng/mL.
Vitamin D sufficiency has been defined as serum 25(OH)D levels of 30-100 ng/mL.
Vitamin D toxicity is observed when serum 25(OH)D levels are greater than 100 ng/mL.
--------------------------------------------------------------------------------
Remarks: Please correlate results clinically.
--------------------------------------------------------------------------------
Iron Profile Serum Sample
Accession No: DEMO_BARCODE Collected On: 21-Jan-25 13:40 Received On: 21-Jan-25 14:39 Approved On: 21-Jan-25 15:20
Observation Result Unit Biological Ref. Interval Method
Iron 129 µg/dL 49-181 Pyridylazo Dye
Total Iron Binding Capacity 386 µg/dL 261 - 462 Chromazurol B
Transferrin Saturation 33.42 % 19 - 39 Calculated
-----------------------------------------------------------------------------------------------------------------
Analyzer: Fully Automated Biochemistry and Immunology VITROS 5600
Technology:
- Iron: Dry Chemistry (VITROS MicroSlide, MicroSensor & Intellicheck Technology)
- TIBC: VITROS MicroTip, MicroSensor & Intellicheck Technology
---------------------------------------------------------------------------------------------------------------
Remarks: Please correlate with clinical conditions.
---------------------------------------------------------------------------------------------------------------
In case of any unexpected or alarming results, please contact us immediately for re-confirmation, clarifications, and rectifications, if needed.
Patient Name : Demo Patient Name Lab No : Demo Visit No
Age / Sex : 60 Y / M Registration On : 21-Jan-25 13:40
Referred By : DEMO HOSPITAL Patient ID : UHID.DEMO.001
Centre : HOD Head Office
This is a Sample Report - Actual report will vary in values, format, ranges etc
Scan to Validate
Page 11 of 13
Sample Report
Hb A1c EDTA Whole Blood Sample
Accession No: DEMO_BARCODE Collected On: 21-Jan-25 13:40 Received On: 21-Jan-25 14:31 Approved On: 21-Jan-25 17:35
Observation Result Unit Biological Ref. Interval Method
HbA1C 5.7 % 4.8-5.7 HPLC
90 Day Average Blood Glucose 116.89 mg/dl 90 - 120 Calculated
----------------------------------------------------------------------------------------------------------------------------------------
Interpretation as per American Diabetes Association (ADA) Guidelines
Reference Group Non diabetic adults >=18 years At risk (Prediabetes) Diagnosing Diabetes Therapeutic goals or glycemic
control
HbA1c in % 4.0-5.6 5.7-6.4 >= 6.5 <7.0
----------------------------------------------------------------------------------------------------------------------------------------
Note:
Presence of Hemoglobin variant and /or conditions that affect red cell turnover must be considered particularly when the HbA1c result does not correlate with the
patient’s blood glucose levels.
Factors That Interfere With Hba1c Measurement: Hemoglobin variants, elevated fetal hemoglobin (HbF) and chemically modified derivatives of hemoglobin
(e.g. carbamylated Hb in patients with renal failure) can affect the accuracy of HbA1c measurements
Factors That Affect Interpretation Of Hba1c Results: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g., recovery from
acute blood loss, hemolytic anemia, Hbss, HbCC, and HbSC) will falsely lower HbA1c test results regardless of the assay method used. Iron deficiency anemia is
associated with higher HbA1c
Since HbA1c Reflects long term Fluctuations in the blood glucose concentration, a diabetic patient who is recently under good control may still have a high
concentration of HbA1c. Converse is true for a diabetic previously under good control but now poorly controlled.
Target goals of < 7.0% may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular co-morbid conditions,
targeting a goal of >7.0 % may not be appropriate.
Any condition that shortens erythrocyte survival such as sickle cell disease, pregnancy (second and third trimesters), hemodialysis, recent blood loss of transfusion ,
or erythropoietin will falsely lower HbA1c results regardless of the assay method
In patients with HbA1c level between 7-8%, Glycemark (1,5 Anhydro-glucitol) test may be done to identify those with more frequent and extreme hyperglycemic
excursions.
----------------------------------------------------------------------------------------------------------------------------------------
Remarks: Please correlate results with clinical conditions.
----------------------------------------------------------------------------------------------------------------------------------------
In case of any unexpected or alarming results, please contact us immediately for re-confirmation, clarifications, and rectifications, if needed.
Free Thyroid Test [FT3,FT4,TSH] Serum Sample
Accession No: DEMO_BARCODE Collected On: 21-Jan-25 13:40 Received On: 22-Jan-25 15:52 Approved On: 22-Jan-25 17:35
Observation Result Unit Biological Ref. Interval Method
Free Triiodothyronine [FT3] 2.85 pg/mL 2.77 - 5.27 CLIA
Free Thyroxine [FT4] 0.85 ng/dL 0.78 - 2.19 CLIA
Thyroid Stimulating Hormone (TSH) 0.91 mlU/L 0.46-4.68 CLIA
Patient Name : Demo Patient Name Lab No : Demo Visit No
Age / Sex : 60 Y / M Registration On : 21-Jan-25 13:40
Referred By : DEMO HOSPITAL Patient ID : UHID.DEMO.001
Centre : HOD Head Office
This is a Sample Report - Actual report will vary in values, format, ranges etc
Scan to Validate
Page 12 of 13
Sample Report
-----------------------------------------------------------------------------------------------------------------
Note:
1. TSH Levels are subject to circadian variation, reaching peak levels between 2-4 AM & the minimum between 6-10 PM. The variation is of the order of 50-206%
Hence time of the day has influence on the measured serum TSH concentrations (Reference:Tietz Textbook of Clinical Chemistry & Molecular Diagnostics - 5th Edition
Page 123). Fluctuating TSH value must be Clinically correlated.
2. Circulating TSH levels are known to show a circadian rhythm & diurnal variation. The diagnosis based on one TSH value which fluctuates is not reliable. Clinical
correlation is mandatory.
3. Values <0.03 ulU/mL need to be clinically correlated due to presence of a rare TSH variant in some individuals.
---------------------------------------------------------------------------------
Remarks:Please correlate results clinically.
---------------------------------------------------------------------------------
In case of any unexpected or alarming results, please contact us immediately for re-confirmation, clarifications, and rectifications, if needed.
ESR EDTA Whole Blood Sample
Accession No: DEMO_BARCODE Collected On: 21-Jan-25 13:40 Received On: 21-Jan-25 14:31 Approved On: 21-Jan-25 16:01
Observation Result Unit Biological Ref. Interval Method
ESR 9 mm/hr <20 Modified Westergren
--------------------------------------------------------------
Clinical Notes for ESR:
Increased ESR is seen in:
- In any chronic infection
- Active rheumatic fever
- Acute myocardial infection
- Nephrosis
- All type of shocks
Decreased ESR is seen in:
- Newborn infants
- Polycythemia
- Congestive heart failure
- Sickel cell anaemia
--------------------------------------------------------------
Remarks: Please correlate results with clinical conditions.
--------------------------------------------------------------
In case of any unexpected or alarming results, please contact us immediately for re-confirmation, clarifications, and rectifications, if needed.
Patient Name : Demo Patient Name Lab No : Demo Visit No
Age / Sex : 60 Y / M Registration On : 21-Jan-25 13:40
Referred By : DEMO HOSPITAL Patient ID : UHID.DEMO.001
Centre : HOD Head Office
This is a Sample Report - Actual report will vary in values, format, ranges etc
Scan to Validate
Page 13 of 13
Sample Report


=== STEP 2: Full extraction + embed + vdb upload ===
Starting full ingestion...
Processing:   0%|                                                                            | 0/1 [00:00<?, ?doc/s]INFO:nv_ingest_client.client.client:Starting batch processing for 1 jobs with batch size 32.
Processing: 100%|████████████████████████████████████████████████████████████████████| 1/1 [00:15<00:00, 15.10s/doc]INFO:nv_ingest_client.client.client:Batch processing finished. Success: 0, Failures: 1. Total accounted for: 1/1
Processing: 100%|████████████████████████████████████████████████████████████████████| 1/1 [00:15<00:00, 15.10s/doc]
WARNING:nv_ingest_client.client.interface:Job was not completely successful. 0 out of 1 records completed successfully. Uploading successful results to vector database.
Total time: 15.10 seconds

Results:  0
Failures: 1

=== FULL PIPELINE FAILURE DETAILS ===

--- Failure [0] ---
('1:Docs/PK0016.pdf', '[]: failed\nFailed to process the message.\n↪ Event that caused this failure: annotation::8bdfeeab-714e-4f5f-b9fe-fd0423445827 -> Error in on_data: extract_primitives_from_pdf: Error processing PDF bytes: _orchestrate_row_extraction: error: Error during NimClient inference [yolox-page-elements, http]: 403 Client Error: Forbidden for url: https://ai.api.nvidia.com/v1/cv/nvidia/nemoretriever-page-elements-v2')
Killed subprocess group 2238869
